Real-world evidence on prognostic value of MRD in multiple myeloma using flow cytometry

Minimal residual disease (MRD) is a key prognostic factor in multiple myeloma (MM), with MRD negativity now accepted as an early endpoint for accelerated drug approval. In this retrospective study of 331 newly diagnosed MM patients, MRD negativity after stem cell transplantation was linked to significantly improved progression-free survival (PFS) and overall survival (OS). The study also found that MRD-positive patients benefited from lenalidomide maintenance, whereas MRD-negative patients did not, underscoring the importance of MRD status in guiding treatment decisions.